Rectal Cancer

P2, N=90, Not yet recruiting, Sichuan Huiyang Life Science and Technology Corporation

P=N/A, N=90, Recruiting, Mount Sinai Hospital, Canada | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2026

P2, N=44, Active, not recruiting, Harbin Medical University

For elderly patients undergoing laparoscopic rectal cancer surgery in the Trendelenburg position, individualized PEEP titration based on static lung compliance is associated with lower postoperative lung ultrasound scores (primarily located in the lateral and posterior zones) and may potentially alleviate atelectasis. This strategy is associated with improved intraoperative lung compliance, decreased driving pressure, and increased postoperative serum SP-A concentration, potentially providing intraoperative lung protection. Future studies should evaluate hard clinical outcomes, such as postoperative pulmonary complications (PPCs), as primary endpoints.

P=N/A, N=123, Completed, Istanbul Saglik Bilimleri University

P=N/A, N=47, Completed, Beijing Friendship Hospital | Not yet recruiting --> Completed | N=26 --> 47 | Trial completion date: Mar 2024 --> May 2026 | Trial primary completion date: Dec 2023 --> Apr 2026

We report a case of metastatic CRC that achieved CR following second-line treatment with FOLFIRI plus ramucirumab after disease progression on first-line FOLFOX plus panitumumab therapy...In the present case, a watch-and-wait strategy was selected to prioritize organ preservation. Given the lack of consensus, further investigation is required to define the optimal strategy for patients achieving CR.

P=N/A, N=50, Recruiting, Centre Paul Strauss | Trial completion date: Sep 2026 --> Jul 2030

In colon cancer, the adverse prognostic signal within T4N0 disease appears to be driven primarily by T4bN0. These findings support reconsideration of current staging paradigms, particularly for T4bN0 colon cancer, and warrant further prospective validation of risk-adapted postoperative strategies.

We present a 57-year-old man with KRAS G13D-mutant, liver-dominant metastatic rectal adenocarcinoma and recurrent fluoropyrimidine-associated coronary vasospasm precluding 5-fluorouracil and capecitabine. After multimodal first-line therapy and regorafenib, trifluridine/tipiracil (TAS-102) plus bevacizumab was initiated and integrated with liver-directed treatments for oligoprogressive disease. This combined strategy achieved approximately 16.6 months of disease control, substantially exceeding the median progression-free survival reported in the SUNLIGHT trial, with manageable hematological toxicity and preserved performance status. This case highlights the value of TAS-102 plus bevacizumab combined with focal liver-directed therapy as a feasible long-term strategy for selected patients with oligoprogressive mCRC when fluoropyrimidines cannot be used.

P=N/A, N=216, Recruiting, Sun Yat-sen University

The minimally invasive anatomical approach allowed precise vascular control and achievement of oncologically adequate margins in a technically demanding central segment. Larger clinical series are needed to define optimal management strategies and long-term oncologic outcomes in this setting.